Developing in Vivo Gene Editors that Target Liver Diseases

Joe Truitt, CEO of iECURE, discusses his company’s in vivo gene editing therapies, its focus on liver diseases, and how it’s leveraging its partnership with the University of Pennsylvania’s Gene Therapy Program.